Featured Publications
MPEP Lowers Binge Drinking in Male and Female C57BL/6 Mice: Relationship with mGlu5/Homer2/Erk2 Signaling
Huang G, Thompson SL, Taylor JR. MPEP Lowers Binge Drinking in Male and Female C57BL/6 Mice: Relationship with mGlu5/Homer2/Erk2 Signaling. Alcohol Clinical And Experimental Research 2021, 45: 732-742. PMID: 33587295, PMCID: PMC8076072, DOI: 10.1111/acer.14576.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBinge DrinkingDose-Response Relationship, DrugDrug Evaluation, PreclinicalExcitatory Amino Acid AntagonistsFemaleHomer Scaffolding ProteinsMaleMAP Kinase Signaling SystemMice, Inbred C57BLMitogen-Activated Protein Kinase 1Nucleus AccumbensPyridinesReceptor, Metabotropic Glutamate 5Septal NucleiSex CharacteristicsConceptsEffects of MPEPFemale C57BL/6 miceAlcohol intakeAlcohol consumptionNegative allosteric modulatorsLocomotor activityC57BL/6 miceFemale miceMale miceHomer2 expressionBinge drinkingMetabotropic glutamate receptor 5MGlu5 negative allosteric modulatorsSex differencesBinge alcohol consumptionGlutamate receptor 5Dose-response effectExcessive alcohol useERK2 expressionDose-response relationshipPotential sex differencesERK2 signalingBed nucleusNucleus accumbensStria terminalis
2021
Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants
Thompson SL, Gianessi CA, O'Malley SS, Cavallo DA, Shi JM, Tetrault JM, DeMartini KS, Gueorguieva R, Pittman B, Krystal JH, Taylor JR, Krishnan-Sarin S. Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants. Frontiers In Psychiatry 2021, 12: 709559. PMID: 34531767, PMCID: PMC8438169, DOI: 10.3389/fpsyt.2021.709559.Peer-Reviewed Original ResearchNMDA receptorsSrc/FynAlcohol consumptionEffect of saracatinibVehicle 2 hChronic alcohol useDays of treatmentDSM-IV criteriaMore effective treatmentsNumber of drinksGlutamatergic systemAdditional drinkAlcohol drinkingAdditional dosesEthanol exposureEffective treatmentNR2B subunitAlcohol abuseHuman studiesPriming drinkAlcohol cravingSaracatinibDrinking paradigmNovel pharmacotherapeuticsHuman participants